Drugs / Iclepertin
Trials 28 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 121 trials | ||||||
| Phase 1 | NCT06070597 | Jan → Jun 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05731895 | Mar → Dec 2023 | liver disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05723874 | Mar → May 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05718843 | Feb → Oct 2023 | impaired renal function disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05613777 | Nov 2022 → Oct 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05347004 | Oct → Dec 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05258110 | Mar → May 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05076409 | Oct 2021 → Jan 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04602221 | Dec 2020 → Aug 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03988803 | Jul → Oct 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03905096 | Apr → Aug 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03817476 | Feb → May 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03783000 | Jan → Mar 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03654170 | Sep → Nov 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03082183 | Mar → Jun 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02783040 | Sep → Oct 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02383888 | May → Aug 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02362516 | Feb → Jun 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02337283 | Jan → Nov 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02342717 | Jan → Mar 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02068690 | Mar → Sep 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03859973 | Apr 2019 → Sep 2022 | schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02788513 | Aug 2016 → Sep 2019 | Alzheimer disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02832037 | Jul 2016 → Dec 2019 | schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05211947 | Mar 2022 → Feb 2025 | schizophrenia | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 3 | NCT04846868 | Sep 2021 → Sep 2024 | schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT04846881 | Aug 2021 → Oct 2024 | schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT04860830 | Aug 2021 → Oct 2024 | schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iclepertin | “This substudy from a Phase II, randomized, double-blind, placebo-controlled, parallel-group study investigating the safety and efficacy of the novel glycine transporter-1...” PMID 35953474 ↗ Aug 2022 |
| Known as | BI 425809 | “iclepertin (BI 425809)” NCT05258110 ↗ |
| Action | Inhibit | “Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers” PMID 29076028 ↗ Apr 2018 |
| Modality | Small molecule | — CHEMBL5314576 ↗ |
| Route | Oral | “Single Rising Oral Doses of BI 425809 in Healthy Male Subjects” NCT02068690 ↗ |